

#### International Rare Donor Panel

The IRDP database can only be accessed by authorised users.

Access the database



### **Rare Donor Program**

### **Country: Finland**

International Society of Blood Transfusion

Rare Donor Program		
Rare Donor Program	Yes	
National Regional or Facility based	National	
Number of Rare Donors	220	
Definition of Rare	Someone who is negative for a high prevalence antigen where the frequency of this antigen negative phenotype is less than 1 in 1000. People with a combination of antigen negative phenotypes where that combination has a prevalence of less than 1 in 1000 may also be considered rare.	
Are the donors listed in the International Rare Donor Panel	Yes	
Frozen Inventory	Yes	
How are Rare Donors found	Selected donor phenotyping and genotyping Corresponding antibody detected in a donor, patient or antenatal samples Family studies	
Number of Rare Donor Units used per year	50 units per year	
ISBT Rare Donor WP Blood Shipment form used	Yes	
Outcome of incompatible transfusion form used	Yes	
Most difficult types to find	Rh null, K null, U-, Vel -, Dib-	
Phenotypes confirmed by molecular testing	Most new rare donors identified have molecular testing performed and serology where antisera is available	

Phenotype	Total Active Donors	Group O	O Positive	O Negative	Other ABO/Rh
Co(a-)	14	9	8	1	5
Di(b-)	3	3	3	0	0
GE:-2,-3	1	1	1	0	0
Jk(a-b-)	28	13	8	5	15
Js(b-)	1	1	1	0	0
K+k-	47	25	15	10	22
Kp(b-)	4	2	2	0	2
Lu(a-b-)	1	1	1	0	0
Lu(b-)	6	4	3	1	2
Lu:-12	1	0	0	0	1
LW(a-)	19	11	10	1	8
P neg	7	2	2	0	5
PP1Pk-	1	1	1	0	0
Rh:-51	7	5	5	0	2
U+var P2	1	1	1	0	0
Vel(-)	5	3	2	1	2
Yt(a-)	3	1	0	1	2
D neg e neg (r"r")	2	2	0	2	0

### How are your rare donors found?

	Yes / No	Method	Comments
Extended phenotyping donors	Yes	All donors typed for C, E, c, e and K - K+ donors typed for k - Immucor Neo Iris. Selected donors (20 % donations) typed for Fy <sup>a</sup> , Fy <sup>b</sup> , Jk <sup>a</sup> , Jk <sup>b</sup> , M, S and s – Bio-Rad IH-1000	In most cases the rare phenotype is confirmed with genotyping
Extended genotyping donors	Yes	Selected donors (5 % donations) genotyped using ID CoreXT	Where antisera is available genotype is confirmed by serology.
Family studies	Yes	Recruitment of siblings of donors, patients and pregnant women.	<ul> <li>Information to recruit donor siblings is provided by phone or letter and inquiry form done by medical doctors from FRCBS.</li> <li>Siblings of patients and pregnant women are contacted via local blood centre or maternity care centre by the phone call, letter and inquiry form done by laboratory specialists from FRCBS.</li> </ul>
Antibody investigations	Yes	All donors are screened for red cell antibodies at the first donation and after immunizing events using the Immucor Neo Iris. Complicated identification cases of patient and all the antenatal samples in Finland are centralized to the FRCBS National Reference laboratory.	Antibody identification may require the use of many different techniques, including molecular testing to determine the specificity.
Other		NA	NA





## **Red Cell Product Specifications**

### **Country: Finland**

International Society of Blood Transfusion

	Donor Select	tion	
Donation	Voluntary		
Age or Weight Restrictions		18-71 years, <u>&gt;</u> 50 kg	
Donation Interval	Female 3 month	is, male 2 months (minimum interval)	
Sexual Activity Precautions	Positive for HIV, Hepatitis B/C, or HTLV	Donor positive: Permanent deferral. If the donor has a resolved HBV (> 2 years), donation is possible if HBsAb is ≥ 200 IU/L. Sex partner positive: Deferral when ongoing relationship, 4 month deferral after last sex contact. Partner HBV carrier: Donation is possible after vaccination and HBsAb proven positive	
	Male to male sex	4 month deferral	
	Sex worker or contact with sex worker	4 month deferral	
Travel Exclusions	Dengue	28 day deferral	
If donor has returned from an area endemic for the listed	Ebola	Min. 8 weeks (usually 6 months because of malaria endemic region)	
infectious illnesses	Malaria	6 month deferral. Targeted antibody screening for donors, who have had malaria or have lived in an endemic region under the age of 5 years for 6 months or longer.	
	West Nile Virus	28 day deferral	
Lifestyle	Acupuncture, piercing or tattoo	4 month deferral (no deferral for acupuncture performed by a qualified health professional)	
	Drug use (Non-prescribed injected)	Permanent deferral	
	Incarceration	NA (risk behaviour covered by other questions)	
CJD restrictions	CJD - Donor diagnosed with CJD or knowledge of familial CJD (parents, siblings, offspring, grandparents): Permanent deferral. vCJD - Residency in UK 1980-1996 for more than 6 months or blood transfusion in UK since 1980: Permanent deferral.		
Covid restrictions	COVID19 vaccine administration	No deferral. Exception: If symptoms from vaccination, deferral until feeling well for 2 days.	
	COVID infection	Mild: 10 day deferral from onset, and feeling well for at least 2 days . Fever > 38C: 14 day deferral from recovery. Hospitalisation: 3 month deferral.	
	Household contact	According to the relevant national public health guidelines.	

Provides details of antibody and nucleic acid testing Mark tests as NA when not required Include details of any additional testing required

	Screening test	Risk of blood transfusion transmission
HIV	HIV-1/2 AgAb (incl. HIV p24 Ag) & RNA by ID NAT	< 1 in 1 million risk of blood transfusion transmission
нсу	HCV Ab & RNA by ID NAT	< 1 in 1 million risk of blood transfusion transmission
HBV	HBsAg & HBV DNA by ID NAT	< 1 in 1 million risk of blood transfusion transmission
Syphilis	Treponemal Ab	Not calculated. No reported transfusion transmitted syphilis wo for many decades > the residual risk is extremely low.
HTLV (1 & 2)	NA	Universal leucodepletion. HTLV risk estimated to be very lo Finnish blood donors. Risk assessment 2016: < 1 in 1 million blood transfusion transmission
СМУ	NA	Universal leucodepletion. Leucodepleted blood products a considered CMV safe. Assumption < 1 in 1 million risk of bl transfusion transmission
Zika Virus	NA	ZIKV represents a very low/theoretical risk to blood safety in Finland. Th zika virus circulating/no local transmission in Finland. The number of in ZIKV infections reported in Finland is very low. Universal 28 days travel after visiting countries outside the EU-/ETA-countries.
West Nile Virus	NA	WNV represents a very low risk to blood safety in Finland. Finland is a endemic region; 28 days deferral after visiting areas with an ongoing epidemic.
Babesia	NA	Babesia spp. is considered a very low risk to blood safety in Finland. O case of autochthonous human babesiosis has been reported in Finland
Trypanosoma cruzi (T. cruzi) Chagas Disease	NA	Only a few cases of human Chagas' disease (imported) have been rep Finland. Given the small number of cases reported and the relatively sm of immigrants from endemic regions, T. cruzi represents a low risk to component safety in Finland.
Malaria antibodies	Plasmodium Ab index (targeted testing for donors, who have had malaria or have lived in an endemic region as a child under the age of 5 years)	As an non-endemic region, the risk for malaria transmission through products in Finland is extremely low.

Red Cells	Leucocyte Depleted	Paediatric Leucocyte Depleted	Washed Leucocyte Depleted	
Description	A red cell component obtained by removing the puffy coat and most of the plasma (avg. 18 ml left) after centrifuging whole blood collected into anticoagulant. The red cells are resuspended in additive solution and are filtered to remove most leucocytes.	A leucocyte depleted red cell component divided into three packs of equal volume for the purpose of reducing donor exposure for small paediatric transfusions and to minimise product wastage.	Red cells leucocyte depleted are washed three times with sterile SAG-M solution using a manual process to remove the majority of unwanted plasma proteins, antibodies and electrolytes. The washed red cells are resuspended in SAG-M additive solution.	
Anticoagulant	Citrate phosphate dextrose (CPD)	Citrate phosphate dextrose (CPD)	Citrate phosphate dextrose (CPD)	
Additive Solution	Saline adenine glucose mannitol (SAG-M)	Saline adenine glucose mannitol (SAG-M)	Saline adenine glucose mannitol (SAG-M)	
Average volume	260 ml 90 ml 267 ml			
Storage Duration	35 days         35 days         14 days			
Leukofiltration	leucocyte reduced to <1x10^6/unit			
Storage Temperature	2°C to 6°C			
Transport Temperature	2°C to 10°C			
Modifications	Phenotyped, irradiated			
Irradiation Policy	Gamma irradiation: 25-50Gy or X-ray irradiation			

	For Intrauterine Transfusion	Frozen Leucocyte Depleted
Description	A hyper-concentrated red cell component less than five days old with a haematocrit of 0.70–0.85 obtained by removing most of the plasma (avg. 1.8 ml left) /additive solution. The red cells are resuspended in 0.9% saline to achieve the desired haematocrit.	Used for patients with rare red cell phenotypes, or multiple red cell antibodies when liquid-preserved blood cannot fulfil demands. Can be supplied internationally as a frozen product and thawed locally.
Anticoagulant	Citrate phospahte dextrose (CPD)	Citrate phosphate dextrose (CPD)
Additive Solution	0,9% NaCl	Glycerol is added to red cells as a cryoprotectant
Leukofiltration	leucocyte reduced to <1x10^6/unit	leucocyte reduced to <1x10 <sup>^</sup> 6/unit
Average volume	88 ml	Thawed unit after deglyceration and resuspending to additive solution 275 ml
Storage Temperature	2°C to 6°C	≤ -65°C Frozen within 7 days of collection 2°C to 6°C once thawed
Transport Temperature	2°C to 10°C	≤ -65°C 2°C to 10°C once thawed
Storage Duration	9 hours post hyperconcentration	10 years
Irradiation Policy	Gamma irradiation: 25-50Gy or X-ray irradiation Red cells for IUT must be irradiated.	Not a registered process
Other	ABO, RhD compatible with both mother and fetus, K negative. Should be antigen-negative for maternal alloantibodies, IAT crossmatch compatible with the maternal plasma. If the fetal blood group is unknown use group O, RhD negative red cells.	Prior to transfusion, glycerol must be removed from the thawed component by washing the cells with NaCl. After washing, the red cells are resuspended in additive solution (SAGM) or and must be used within 7 days hours. There will be some loss of red cells during the freezing and thawing process. When requesting frozen red cells it should be noted that thawing and processing time is several hours.






# **Frozen Inventory**

### **Country: Finland**

International Society of Blood Transfusion

General Information		
Freezing Method	Glycerolyte 57 using Haemonetics ACP215 cell washer	
Frozen Expiry (years)	10 years	
Storage Temperature	≤ -65°C	
Can inventory be issued and sent frozen	Yes	
Thawing Method	Deglycerolisation with 12% and 0.9% saline using Haemonetics ACP215 cell washer	
Thawed Expiry (days)	7 days	
Additive Solution	SAGM	
Irradiation Policy	Not a registered process.	
IUT and Neonate use	Not a registered process, but may be issued as a patient tailored product	
Supply out of date Policy	Exceptionally rare units may be retained beyond expiry. If required for issue they are released with a shorter shelf-life of 3 days.	

Product Specifications		
Volume	286 -300 ml	
Supernatant Haemoglobin	< 0,2 g/unit	
Haematocrit	0.37 – 0.53 (L/L)	
Haemoglobin	≥36 (g/unit)	
Osmolarity	≤382 (mOSm/KgH2O)	
Residual leucocyte content	< 1.0 x 10 <sup>6</sup> /unit)	
Sterility	No growth	
Other	Questionary sent with thawed unit: Was unit transfused? What was the indication for transfusion? Hb before and after transfusion Were there any complications?	





## Ordering and Shipping

### **Country: Finland**

International Society of Blood Transfusion

Exporting		
Request form available	No, communication done by email according SOP.	
Government Requirements	NA	
Regulatory Requirements	Rare units can be only delivered to the health service organizations.	
Rare Donor Program Requirements         Preferred courier – World Couriers		
Other	NA	

Importing		
Government Requirements	NA	
Regulatory Requirements	When importing blood units outside the EU, permissions from regulatory authority is needed including certificate of origin for the supplying blood service.	
Rare Donor Program Requirements	A copy of all test results for the donation e.g. blood group, phenotype and infectious disease screening Temperature monitored transport (Preferred courier – World Couriers).	
Other	NA	